Satellos Bioscience (MSCL) Q1 2025 earnings summary

Executive summary

• Completed enrollment in Phase 1b trial for adult DMD patients; data analysis and reporting expected in Q2 2025.

• Received regulatory approval to initiate an 11-month long-term follow-up study for Phase 1b participants.

• Preparing global regulatory filings for a Phase 2 randomized, placebo-controlled proof-of-concept trial in pediatric DMD patients, expected in Q3 2025.

• SAT-3247 demonstrated safety and predictable PK profile in healthy volunteers and initial clinical studies.

Financial highlights

• Cash and short-term investments totaled $41.2 million as of March 31, 2025, down from $48.5 million at December 31, 2024.

• Net loss for Q1 2025 was $6.1 million ($0.04 per share), compared to $5.1 million ($0.05 per share) in Q1 2024.

• R&D expenses increased to $4.5 million in Q1 2025 from $4.4 million in Q1 2024, mainly due to higher clinical trial costs.

• G&A expenses rose to $1.9 million in Q1 2025 from $1.7 million in Q1 2024, driven by higher headcount and stock-based compensation.

Outlook and guidance

• Funds on hand are expected to support operations and planned clinical trials through completion of the Phase 2 POC trial.

• Full Phase 1 data expected to be reported in Q2 2025; Phase 2 trial filings planned for Q3 2025.